[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mitral-valve-regurgitation-degenerative-or-functional\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mitral-valve-regurgitation-degenerative-or-functional":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100433119",false,"NCT04919980","TVMR With the INNOVALVE System Trial - Early Feasibility Study","TWIST-EFS","Inclusion Criteria:\n\n* Clinically significant, symptomatic mitral regurgitation\n* High risk for open-heart surgery\n* Meets anatomical criteria\n\nExclusion Criteria:\n\n* Unsuitable anatomy\n* Patient is inoperable\n* EF\\\u003C25%","ALL","18 Years",{"count":18,"type":19},65,"ESTIMATED","INTERVENTIONAL",[22],"NA","Study to evaluate the safety and performance of the INNOVALVE system",[25],"Mitral Valve Regurgitation (Degenerative or Functional)","RECRUITING","2026-05-26",{"date":29,"type":30},"2026-05-28","ACTUAL",{"date":32,"type":30},"2022-09-01",{"date":34,"type":19},"2031-07-01",{"name":36,"class":37},"Edwards Lifesciences","INDUSTRY",20,{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":48,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":5},"100607413","NCT07188233","Mitral Annular Repair With the CathHELIX™ Transcatheter System in Subjects With FMR","A Study to Evaluate the Feasibility and Safety of Mitral Annular Repair With the CathHELIX™ Transcatheter System in Subjects With Functional Mitral Regurgitation","MARCH","Inclusion Criteria:\n\n* Moderate to severe (3+) or severe (4+) functional mitral regurgitation\n* Left ventricular ejection fraction ≥30%\n* Symptomatic New York Heart Association (NYHA) Class II to IV).\n\nExclusion Criteria:\n\n* Oxygen dependent for COPD\n* Active or suspected endocarditis\n* Severe symptomatic carotid stenosis\n* Has undergone heart transplantation.\n* Severe calcification of the mitral annulus or leaflets\n* Coronary sinus anatomy that may preclude proper treatment with the device",{"count":47,"type":19},5,[22],"Patients with functional mitral regurgitation classified as moderate to severe (3+) or severe (4+) that are symptomatic (NYHA Class II-IV) will be evaluated for treatment using the CathHELIX Transcatheter Mitral Annuloplasty System.",[25],"2025-09-20",{"date":53,"type":30},"2025-09-23",{"date":55,"type":30},"2024-11-16",{"date":57,"type":19},"2026-07",{"name":59,"class":37},"HVR Cardio Oy",""]